Erratum: The effects of statin use on the development of tuberculosis among patients with diabetes mellitus ( Int J Tuberc Lung Dis (2014) 18:6 (717-724) 10.5588/ijtld.13.0854);The effects of statin use on the development of tuberculosis among patients with diabetes mellitus

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 6, 2014, Pages 622-

  Kang, Y A ^a   Choi, N K ^b   Seong, J M ^c   Heo, E Y ^d   Koo, B K ^d   Hwang, S S ^e   Park, B J ^f   Yim, J J ^b   Lee, C H ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Korea Institute of Drug Safety and Risk Management   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

^e Inha University School of Medicine   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

Author keywords

Diabetes mellitus; Statin; Tuberculosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMINOSALICYLIC ACID; ATORVASTATIN; BIGUANIDE DERIVATIVE; CYCLOSERINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ETHAMBUTOL; FLUINDOSTATIN; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; ISONIAZID; MEGLITINIDE; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ICD-10; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RETINOPATHY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SILICOSIS; SOUTH KOREA; TUBERCULOSIS; VERY ELDERLY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PROTECTION; RISK ASSESSMENT; RISK FACTOR; TIME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROTECTIVE FACTORS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84901264722     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.13.0854-e     Document Type: Erratum

References (34)

1. Dooley K E, Chaisson R E. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009; 9: 737-746.
2. Whiting D R, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
3. Jeon C Y, Murray M B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLOS MED 2008; 5: e152.
4. Baker M A, Harries A D, Jeon C Y, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011; 9: 81.
5. World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes. WHO/HTM/TB/2011.15. Geneva, Switzerland: WHO, 2011.
6. Woodward M, Zhang X, Barzi F, et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003; 26: 360-366. (Pubitemid 36929056)
7. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
8. Cholesterol Treatment Trialists' Collaborators (CTT); Kearney P M, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
9. Alegret M, Silvestre J S. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol 2006; 28: 627-656. (Pubitemid 46133012)
10. Falagas M E, Makris G C, Matthaiou D K, Rafailidis P I. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008; 61: 774-785. (Pubitemid 351426059)
11. Merx M W, Liehn E A, Janssens U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109: 2560-2565. (Pubitemid 38720557)
12. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-885. (Pubitemid 39096018)
13. Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007; 35: 372-378. (Pubitemid 46148524)
14. Tleyjeh I M, Kashour T, Hakim F A, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-1667.
15. Choi Y J, Kim H C, Kim H M, Park S W, Kim J, Kim D J. Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005. Diabetes Care 2009; 32: 2016-2020.
16. Peterson AM, Nau D P, Cramer J A, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12. (Pubitemid 46161090)
17. Forrest G N, Kopack A M, Perencevich E N. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect Dis 2010; 10: 152.
18. Vandermeer M L, Thomas A R, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205: 13-19.
19. Magulick J P, Frei C R, Ali S K, et al. The effect of statin therapy on the incidence of infections: a retrospective cohort analysis. Am J Med Sci 2014; 347: 211-216.
20. Myles P R, Hubbard R B, McKeever TM, Pogson Z, Smith C J, Gibson J E. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009; 18: 269-275.
21. Dublin S, Jackson M L, Nelson J C, Weiss N S, Larson E B, Jackson L A. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009; 338: b2137.
22. Hackam D G, Mamdani M, Li P, Redelmeier D A. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367: 413-418. (Pubitemid 43184262)
23. van den Hoek H L, Bos W J, de Boer A, van de Garde E M. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ 2011; 343: d7281.
24. Mira E, Leon B, Barber D F, et al. Statins induce regulatory T-cell recruitment via a CCL1 dependent pathway. J Immunol 2008; 181: 3524-3534.
25. Guyot-Revol V, Innes J A, Hackforth S, Hinks T, Lalvani A. Regulatory T-cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006; 173: 803-810.
26. Maret A, Coudert J D, Garidou L, et al. Estradiol enhances primary antigen-specific CD4 T-cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 2003; 33: 512-521. (Pubitemid 36267617)
27. Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLOS MED 2009; 6: e1000199.
28. Chalubinski M, Broncel M. Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders. Med Sci Monit 2010; 16: RA245-251.
29. Zhang Q, XiaoHP, CuiHY, Sugawara I. Significant increase in natural-killer T cells in patients with tuberculosis complicated by type 2 diabetes mellitus. J Int Med Res 2011; 39: 105-111.
30. Raemer P C, Kohl K, Watzl C. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009; 39: 1456-1465.
31. Stevenson C R, Forouhi N G, Roglic G, et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007; 7: 234.
32. Kim S J, Hong Y P, Lew W J, Yang S C, Lee E G. Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis 1995; 76: 529-533. (Pubitemid 26008709)
33. World Health Organization. Global tuberculsois report, 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
34. Lee C H, Kim K, HyunMK, Jang E J, Lee N R, Yim J J. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013; 68: 1105-1113.